El Baz Hanan, Demerdash Zeinab, Kamel Manal, Atta Shimaa, Salah Faten, Hassan Salwa, Hammam Olfat, Khalil Heba, Meshaal Safa, Raafat Inas
From the Immunology Department, Theodor Bilharz Research Institute, Imbaba, Giza, Egypt.
Exp Clin Transplant. 2018 Feb;16(1):81-89. doi: 10.6002/ect.2016.0226. Epub 2017 Jun 5.
Liver transplant is the cornerstone line of treatment for chronic liver diseases; however, the long list of complications and obstacles stand against this operation. Searching for new modalities for treatment of chronic liver illness is a must. In the present research, we aimed to compare the effects of transplant of undifferentiated human mesenchymal stem cells, in vitro differentiated mesenchymal stem cells, and adult hepatocytes in an experimental model of chronic liver failure.
Undifferentiated human cord blood mesenchymal stem cells were isolated, pro-pagated, and characterized by morphology, gene expression analysis, and flow cytometry of surface markers and in vitro differentiated into hepatocyte-like cells. Rat hepatocytes were isolated by double perfusion technique. An animal model of chronic liver failure was developed, and undifferentiated human cord blood mesenchymal stem cells, in vitro hepato-genically differentiated mesenchymal stem cells, or freshly isolated rat hepatocytes were transplanted into a CCL4 cirrhotic experimental model. Animals were killed 3 months after transplant, and liver functions and histopathology were assessed.
Compared with the cirrhotic control group, the 3 cell-treated groups showed improved alanine aminotransferase, aspartate aminotransferase, albumin, and bilirubin levels, with best results shown in the hepatocyte-treated group. Histopathologic examination of the treated groups showed improved fibrosis, with best results obtained in the undifferentiated mesenchymal stem cell-treated group.
Both adult hepatocytes and cord blood mesenchymal stem cells proved to be promising candidates for cell-based therapy in liver regeneration on an experimental level. Improved liver function was evident in the hepatocyte-treated group, and fibrosis control was more evident in the undifferentiated mesenchymal stem cell-treated group.
肝移植是慢性肝病治疗的基石性治疗方法;然而,该手术存在诸多并发症和障碍。寻找慢性肝病的新治疗方法势在必行。在本研究中,我们旨在比较未分化的人间充质干细胞、体外分化的间充质干细胞和成年肝细胞在慢性肝衰竭实验模型中的作用。
分离未分化的人脐带血间充质干细胞,进行传代培养,并通过形态学、基因表达分析、表面标志物的流式细胞术进行鉴定,然后在体外分化为肝细胞样细胞。采用双重灌注技术分离大鼠肝细胞。建立慢性肝衰竭动物模型,将未分化的人脐带血间充质干细胞、体外肝源性分化的间充质干细胞或新鲜分离的大鼠肝细胞移植到四氯化碳诱导的肝硬化实验模型中。移植后3个月处死动物,评估肝功能和组织病理学。
与肝硬化对照组相比,3个细胞治疗组的丙氨酸氨基转移酶、天冬氨酸氨基转移酶、白蛋白和胆红素水平均有所改善,其中肝细胞治疗组效果最佳。治疗组的组织病理学检查显示纤维化有所改善,未分化间充质干细胞治疗组效果最佳。
在实验水平上,成年肝细胞和脐带血间充质干细胞均被证明是肝脏再生中基于细胞治疗的有前景的候选者。肝细胞治疗组肝功能改善明显,未分化间充质干细胞治疗组对纤维化的控制更明显。